
Accepted Manuscript

Title: CRAC Channels as Targets for Drug Discovery and Development

Author: Kenneth A. Stauderman



PII:	S0143-4160(18)30080-0
DOI:	https://doi.org/10.1016/j.ceca.2018.07.005
Reference:	YCECA 1960

To appear in: Cell Calcium

 Received date:
 2-5-2018

 Revised date:
 16-7-2018

 Accepted date:
 16-7-2018

Please cite this article as: Stauderman KA, CRAC Channels as Drug Discovery Cell Calcium Targets for and Development, (2018),https://doi.org/10.1016/j.ceca.2018.07.005

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Review


CRAC Channels as Targets for Drug Discovery and Development

Kenneth A. Stauderman ^a *

^a CalciMedica, Inc., 505 Coast Blvd. South, Suite 202, La Jolla, CA 92037, United States

* Corresponding author: Tel.: +1 858 952 5502

Email address: ken@calcimedica.com



 Ca^{2+} release from the endoplasmic reticulum (ER) is triggered by the opening of IP₃ receptors (IP₃R) or by other means. The resulting decrease in ER Ca²⁺ levels is sensed by STIM1, which then oligomerizes and gates Orai1 in the plasma membrane. Ca²⁺ entry via Orai1-containing CRAC channels can activate intracellular signaling pathways and can be pharmacologically blocked by inhibitors, resulting in potentially beneficial or undesirable effects. An image of a potential binding pocket in Orai1 for CRAC channel inhibitors is shown at right, showing the drug-bound pocket superimposed on the crystal structure of Orai1.

Highlights of Review by Kenneth A. Stauderman

- Numerous high-throughput screens or other approaches have identified CRAC channel modulators
- For these compounds to advance, potency, selectivity, efficacy, pharmacokinetic, safety, and toxicological concerns must be addressed
- Orai1 and STIM1 are currently the most attractive CRAC channel components to target
- A handful of potent and selective CRAC channel inhibitors have now reached clinical trials in humans

Download English Version:

https://daneshyari.com/en/article/8463323

Download Persian Version:

https://daneshyari.com/article/8463323

Daneshyari.com